.jpg "Lemaitre Vascular (NASDAQ: LMAT)")
Canaccord Genuity analyst Jason Mills maintained a Hold rating on Lemaitre Vascular (NASDAQ: LMAT) today and set a price target of $35. The company’s shares opened today at $36.96.
According to TipRanks.com, Mills is a top 25 analyst with an average return of 31.7% and a 76.5% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Boston Scientific Corp, and Staar Surgical Company.
Lemaitre Vascular has an analyst consensus of Moderate Buy, with a price target consensus of $36.75.
See today’s analyst top recommended stocks >>
Based on Lemaitre Vascular’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $3.85 million. In comparison, last year the company had a net profit of $4.63 million.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Lawrence Jasinski, a Director at LMAT sold 1,000 shares for a total of $34,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LeMaitre Vascular, Inc. is a medical device company, which engages in the provision of medical devices for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.
